Mitchell Kaye

Mitchell D. Kaye is a life sciences investor and operator with a career spanning biotech-focused public-market investing, private placements, advisory work, and early-stage angel investing. A Bionomics SEC filing states that Kaye joined Deep Track Capital in January 2021 as head of business strategy and investor relations. Deep Track describes itself as a Greenwich-based investment firm focused exclusively on life sciences, partnering with management teams at public and pre-IPO biotechnology companies.

Before Deep Track, Kaye was COO of BVF, a biotechnology fund, from September 2013 to December 2019. A 2018 Bionomics placement agreement with BVF listed BVF’s notice email as [hidden] and provided BVF with the right to nominate a director while it and related parties held at least 15% of Bionomics’ shares. Kaye served on Bionomics’ board from November 2018 until his resignation effective December 31, 2021.

Earlier in his career, Kaye helped build Xmark Opportunity Partners and Brown Simpson Asset Management. SEC filings describe Xmark Opportunity Partners as focused on publicly traded life sciences companies, and a Wall Street Transcript profile says Kaye oversaw more than $100 million of investment into biotechnology, drug discovery, and medical device companies during his Xmark period. He received a B.A. from Wesleyan University and a J.D. from Northwestern University School of Law.

Kaye is also the founder of Sabbatical Ventures, LLC. Public sources describe Sabbatical Ventures as an investment and advisory vehicle focused on seed-stage companies, and several company/founder announcements identify Kaye or Sabbatical Ventures as an early investor in digital health and neurotechnology companies including Mindstep and Rune Labs.

• Deep Track Capital says it is “focused exclusively on the life sciences industry” and seeks long-term partnerships with “public and pre-IPO biotechnology companies.”
• Deep Track’s stated model includes providing capital plus time, expertise, and network support; it aims to lead transactions and build syndicates, while also joining rounds led by other qualified investors.
• Kaye’s earlier Xmark strategy was life-sciences-specific: in a Wall Street Transcript interview, Xmark was described as focused on “private investments into public micro-cap and small cap life sciences companies.”
• Sabbatical Ventures appears to be Kaye’s seed-stage angel and advisory platform, with verified investments in healthtech/neurotech companies such as Mindstep and Rune Labs.
• His strongest pattern is healthcare with a scientific or clinical angle: biotechnology, drug discovery, medical devices, healthcare reimbursement, digital health, brain health, and Parkinson’s/neurotechnology.